PPIG and neuroblastoma: The rate of cyclophosphamide metabolism is considered to be an important factor in cyclophosphamide-induced toxicity10, and our results highlighted that estimating patients’ cyclophosphamide metabolizing capacity by identification of clinically relevant CYP polymorphisms may predict cyclophosphamide-induced adverse reactions even in neuroblastoma patients.